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Neuroblastoma arises from neural crest cell precursors failing to complete the process of
differentiation. Thus, agents helping tumor cells to differentiate into normal cells can
represent a valid therapeutic strategy. Here, we evaluated whether guanosine (GUO), a
natural purine nucleoside, which is able to induce differentiation of many cell types, may
cause the differentiation of human neuroblastoma SH-SY5Y cells and the molecular
mechanisms involved. We found that GUO, added to the cell culture medium,
promoted neuron-like cell differentiation in a time- and concentration-dependent
manner. This effect was mainly due to an extracellular GUO action since nucleoside
transporter inhibitors reduced but not abolished it. Importantly, GUO-mediated neuron-like
cell differentiation was independent of adenosine receptor activation as it was not altered
by the blockade of these receptors. Noteworthy, the neuritogenic activity of GUO was not
affected by blocking the phosphoinositide 3-kinase pathway, while it was reduced by
inhibitors of protein kinase C or soluble guanylate cyclase. Furthermore, the inhibitor of the
enzyme heme oxygenase-1 but not that of nitric oxide synthase reduced GUO-induced
neurite outgrowth. Interestingly, we found that GUO was largely metabolized into guanine
by the purine nucleoside phosphorylase (PNP) enzyme released from cells. Taken
together, our results suggest that GUO, promoting neuroblastoma cell differentiation,
may represent a potential therapeutic agent; however, due to its spontaneous extracellular
metabolism, the role played by the GUO-PNP-guanine system needs to be further
investigated.
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INTRODUCTION
Neuroblastoma (NB) is the most common extracranial solid
tumor of childhood accounting for approximately 10% of all
pediatric cancers, with most cases diagnosed before 5 years of age.
NB prognosis and clinical course are extremely variable and
depend on the patient’s age, tumor stage, and location. Thus,
patients can be classified into three pretreatment risk groups (low,
intermediate, and high risk) with different outcomes ranging
from “very good” in the low-risk group, with the possibility of
spontaneous regression, to “poor” outcome in the high-risk group
with reduced chances of survival (Whittle et al., 2017; Newman
et al., 2019).
Treatment is tailored according to the risk assignment. A
very intensive approach is used for high-risk patients, with
treatment options including chemotherapy, surgical resection,
high-dose chemotherapy with autologous stem cell rescue,
radiotherapy, immunotherapy, and differentiating therapy
(Smith and Foster, 2018). Interestingly, this last approach is
based on the knowledge that NB derives from neural crest cell
precursors failing to differentiate, thus remaining blocked at
an undifferentiated stage. Therefore, agents able to induce cell
differentiation are an attractive therapeutic approach.
However, few agents are available to this aim, and retinoic
acid (RA) is the most commonly used but, unfortunately,
resistance to this agent is frequent (Reynolds et al., 2003).
This highlights the need of developing new potential
differentiating agents.
Guanine-based purines are a group of naturally occurring
purines including guanosine mono-, di-, and tri-phosphate
nucleotides (GMP, GDP, and GTP, respectively), the
nucleoside guanosine (GUO), and the nucleobase guanine
(GUA). In addition to well-known intracellular roles
(i.e., regulation of G-protein activity linked to metabotropic
receptors; formation of the second messenger cyclic
GMP–cGMP-), growing evidence pointed out important
extracellular effects of GTP and GUO, suggesting that they
maybe considered as neuromodulatory signaling agents
regulating many different physiological functions at both the
central and peripheral nervous system (Di Liberto et al., 2016;
Tasca et al., 2018). Among these, it is potentially relevant to NB
management the GUO capacity to induce the differentiation of
several cell types, as demonstrated by in vivo and in vitro studies.
Indeed, GUO treatment stimulated neurogenesis in a rat model of
Parkinson’s disease (Su et al., 2009), and its chronic
administration increased differentiated neurons in mouse
hippocampal dentate gyrus (Bettio et al., 2016). Again, in
hippocampal, cerebellar, and pheochromocytoma (PC12) cell
cultures, GUO stimulated neurite outgrowth, and in PC12
cells, this effect was enhanced by the copresence of nerve
growth factor (Gysbers and Rathbone, 1996; Böcklinger et al.,
2004; Bau et al., 2005). GUO also promoted B16F10 melanoma
cell differentiation and inhibited cell motility, leading to a
decreased melanoma malignancy (Naliwaiko et al., 2008).
Noteworthy, Guarnieri et al. (2009) reported that extracellular
GUO induced a mature neuronal phenotype in NB cells, but the
signaling pathways involved have not been investigated.
Altogether, these findings represented the natural premise that
prompted us to further investigate the differentiation effect of
GUO on a human NB cell line, SH-SY5Y, trying to identify some
pathways involved in this potential effect. In parallel, we
evaluated the activity of purine nucleoside phosphorylase
(PNP), the enzyme involved in GUO conversion into GUA,
since it is expressed in almost all tissues (Moriwaki et al.,
1999) and might deeply affect the activity of GUO on cells. In
our opinion, results obtained in this study could open the way to
identify new therapeutic agents to implement the differentiation-
based therapies in NB.
MATERIALS AND METHODS
Materials and Chemicals
The human SH-SY5Y cell line was purchased from European
Collection of Authenticated Cell Cultures (Salisbury,
United Kingdom); NG-nitro-L-arginine methyl ester
(L-NAME), GF109203X, dipyridamole, and LY294002 from
Tocris (Milan, Italy); and all other drugs, antibodies, and
reagents were obtained from Sigma-Aldrich unless otherwise
stated.
Cell Culture and Treatment
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM)/F12 medium supplemented with 2 mM
L-glutamine and 1% penicillin/streptomycin and different
concentrations of inactive fetal bovine serum (FBS, 0–10%)
and maintained in a humidified atmosphere of 5% CO2 at
37°C. For evaluating the neuritogenic effect of GUO, cells were
treated with various concentrations (GUO 1–300 µM) for
different times (24–96 h). Medium containing GUO was
changed every 48 h. When used, the inhibitors of nucleoside
transporters, propentofylline 100 µM, S-(4-nitrobenzyl)-6-
thioinosine (NBTI) 10 μM, and dipyridamole 10 μM were
added to the medium 1 h before and during 48 h GUO
treatment. In some experiments, cells were treated 30 min
before and during all GUO treatment, with the A1 adenosine
receptor antagonist (1,3-dipropyl-8-cyclopentylxanthine-
DPCPX-100 nM), the A2A receptor antagonist ([4-(2-[7-
amino-2-{2-furyl}{1,2,4}triazolo{2,3a}{1,3,5}triazin-5-ylamino]
ethylphenol]-ZM241385–50 nM), or with the selective inhibitors
of 1) phosphatidyl inositol-3-kinase (PI3K) (LY294002, 25 µM),
2) protein kinase C (PKC) (GF109203X, 1 µM), 3) soluble
guanylate cyclase (sGC) (oxadiazolo[4,3-a]quinoxalin-1-
one–OQD-, 10 µM), 4) nitric oxide synthase (NOS) (L-NAME,
5 µM), or 5) heme oxygenase (HO) (zinc protoporphyrin IX
-ZnPP-1 µM).
Neurite Outgrowth Assay
To evaluate the effect of test compounds on neurite outgrowth, at
the end of each experiment, cells were photographed using an
Axiocam MRC 5 camera connected to an upright Zeiss Axiovert
200 microscope equipped with an objective 20X Plan-Apo/0.75
NA, total magnification 200x (Zeiss, Jena, Germany). Pictures
were taken from 3 to 5 independent microscopic fields from at
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least 3 independent experiments under blind conditions. Images
were acquired using the AxioVision software in bright field
settings (Zeiss). For each experiment, at least 100 cells were
counted and the number of neuron-like differentiated cells,
defined as cells with one or more neurites longer than the
diameter of the cell body, was determined to evaluate the
percentage of neurite-bearing cells.
Immunocytochemistry
SH-SY5Y cells were seeded in a six-well culture plate containing
rectangular glass coverslips and exposed to different substances.
Briefly, at the indicated time, cells were fixed in 2%
paraformaldehyde for 30 min and washed with phosphate-
buffered saline. Then, cells were permeabilized with Triton X-
100 for 5 min and subsequently blocked with a solution
containing 1% serum bovine albumin and 5% normal goat
serum (1 h, 37°C). Cells were incubated at 4°C overnight with
primary antibodies: mouse anti-β-tubulin antibody (1:250),
mouse anti-MAP2 antibody (1:250), or mouse anti-NeuN
antibody (1:100). Cells were then washed and stained with the
secondary antibody (1 h, 37°C). Coverslips were rinsed and
mounted with DABCO-glycerol. The observations were made
with a fluorescence microscope Nikon Eclipse E800 and images
acquired by a DMX 1200 photo camera.
Measurement of Extracellular Guanosine
and Guanine Levels and Enzyme Activity
Assay
To evaluate the concentration of extracellular GUO and GUA, at
the indicated time, an aliquot of the medium was taken and
immediately heat-inactivated for 5 min at 70°C to prevent any
further metabolic degradation. After centrifugation, the
supernatant was filtered through 0.2 µm filters (Millipore,
Vindrome, Italy) and analyzed by HPLC as reported below.
Samples containing PNP were obtained as described by
Giuliani et al. (2017). Briefly, SH-SY5Y cells were incubated in
serum-free medium without or with 100 µM GUO. After 6 and
24 h, the medium was taken and the enzyme present was
concentrated using Amicon Ultra 2 ml filters (cutoff 10 K,
Merck Millipore), while cells were scraped in lysis buffer
(5 mM HEPES pH 8.5, 2 mM EDTA, and protease inhibitor
cocktail) and sonicated to obtain cytosolic extracts. Protein
content was quantified using a colorimetric protein assay kit
(Bio-Rad, Segrate, Italy). PNP activity was evaluated by
measuring the transformation of GUO, the enzyme’s substrate,
into GUA by HPLC analysis as previously reported (Giuliani
et al., 2016). Briefly, the enzymatic reaction occurs in HEPES
(50 mM; pH 7.0) containing 50 mM inorganic phosphate plus an
aliquot of the concentrated medium or a cytosolic sample as a
source of PNP. 100 µMGUOwas then added and the mixture was
incubated by shaking at 37°C for 15 min. In the experiments
aimed to evaluate the specificity of the enzyme assay, the PNP
inhibitor, forodesine 1 µM (D.B.A, Segrate, Italy), was added to
the reaction mixture before GUO. The reaction was stopped by
heating the mixture at 70°C for 5 min. After centrifugation, the
supernatant was filtrated before HPLC analysis.
The HPLC (Agilent 1,100 Series, Waldbronn, Germany) was
equipped with a thermostated column compartment, a diode
array detector, and a fluorescence detector. The separation was
achieved by a Phenomenex Kinetex pentafluorophenyl analytical
column (Phenomenex INC., Bologna, Italy) kept at 35°C and
applying a 15-min nonlinear gradient with a flow rate of 1 ml/min
(for further details see Giuliani et al., 2016). The fluorescents
GUO and GUA were monitored at an excitation wavelength of
260 nm and an emission wavelength of 375 nm. PNP activity was
expressed as milli-international units (mIU) being 1 IU of
enzyme the amount of PNP that catalyzes the conversion of
1 μmol of substrate per min.
Statistical Analysis
Data were analyzed by one-way or two-way ANOVA followed by
Tukey’s or Dunnett’s post hoc test for multiple comparisons
using GraphPad Prism software. All data were expressed as
mean ± SEM of at least three independent experiments in
duplicate or triplicate. p values <0.05 were considered
statistically significant.
RESULTS
Guanosine Induces Differentiation of
Human Neuroblastoma SH-SY5Y Cells
Although serum present in the culture medium provides optimal
conditions for cell growth, it can interfere with the differentiation
process, thus differentiation is usually performed by reducing
serum concentrations (Brunner et al., 2010; Magalingam et al.,
2020). However, serum deprivation can cause cell death (Braun
et al., 2011; Rashid and Coombs, 2019). Therefore, we first
evaluated the lowest serum concentration that did not affect
SH-SY5Y cell survival. To this aim, cell viability was assessed by
MTT assay in cultures incubated for 24 h up to 96 h with a
medium containing different serum concentrations (0–10%). As
detailed in the Supplements, either serum-free medium or
medium containing 0.5% serum decreased cellular viability
after 48 h, while the presence of 1% FBS did not modify it.
Conversely, medium containing 5 or 10% FBS caused a time-
and concentration-dependent proliferative effect
(Supplementary Figure S1). Thus, we performed the
subsequent experiments using a culture medium containing
1% serum.
Then, we investigated the effect of increasing concentrations
of GUO (1–300 µM) on NB cell differentiation by calculating the
number of cells bearing neurites with a length major than the cell
body. The GUO effect was first evaluated by exposing cells to 48 h
treatment, a time previously reported as suitable for GUO to
affect PC12 cell differentiation (Gysbers and Rathbone, 1992; Bau
et al., 2005). In comparison to untreated cells, which showed few
and very short neurite-like projections, GUO-treatment
increased in a dose-dependent manner the number of neuron-
like differentiated cells (Figures 1A,B). The maximum effect was
reached at the concentration of 100 μM, whereas the calculated
EC50 value was 49.67 ± 6.22 µM. Next, to appreciate the
neuritogenic activity of GUO over time, we performed a time-
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course study using 50 and 100 µM GUO, able to cause half and
maximal differentiation effects, respectively. In untreated
cultures, the percentage of neuron-like cells was quite
constant, varying from 10 to 20% throughout the observation
period. As expected, differentiation was greater in cells treated
with 100 µM GUO than in those exposed to 50 μM, although in
both cases, the maximal effect was reached after 48–72 h
treatment (Figure 1C).
To further characterize SH-SY5Y cells cultured under our
conditions, we also performed immunocytochemical staining for
specific mature neuronal markers such as βIII tubulin, MAP2
(microtubule-associated protein 2), and NeuN, a nuclear neuron-
specific marker (Soltani et al., 2005; Borsani et al., 2020). We also
compared these results with those obtained with the most
common and established differentiating agent, RA 10 µM
(Kovalevich and Langford, 2013). We found that like RA
10 μM, Guo 100 µM for 48 h increased the expression of the
neuronal markers related to the differentiation compared to
untreated cells (Figure 2). Furthermore, by using phalloidin
staining we monitored the change in F-actin reorganization
and appreciate a time-dependent emersion and extension of
neurites (Supplementary Figure S2).
The Effect of Guanosine on SH-SY5Y
Neuron-Like Cell Differentiation Involves
Different Mechanisms
To evaluate if the GUO differentiating effect was due to its
extracellular activity, as previously reported for some effects
(Giuliani et al., 2012a; Giuliani et al., 2015), nucleoside
FIGURE 1 | Guanosine induces SH-SY5Y neuroblastoma cell differentiation in a dose- and time-dependent manner. (A) For the concentration-response curve,
increasing concentrations (1–300 µM) of GUOwere added for 48 h in medium containing 1% FBS. A non-linear regression analysis was performed and Emax and EC50
were calculated. (B) Representative images of SH-SY5Y cells cultures treated with 0, 50, and 100 μM GUO in medium with 1% FBS after 48 h. (C) For the time-
dependent curve, cell cultures were incubated with GUO (50–100 µM) for different times (0–96 h) in a medium culture containing 1% FBS. In all cases, the number
of differentiated cells, defined as cells having neurites more than one cell body length, was determined using a upright Zeiss Axiovert 200 microscope, total magnification
200x (Zeiss, Jena, Germany). Values are expressed as a percentage of neurite-bearing cells vs untreated cells and represent the mean ± SEM from at least three to five
independent experiments.
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transporter blockers (10 µM NBTI plus 100 µM propentofylline-
PPF- and 10 µM dipyridamole-DYP-) were added 1h before and
during GUO treatment (100 μM, 48 h). The uptake inhibitors
produced only a partial reduction of about 20% of the GUO-
induced effect (Figure 3A), without affecting untreated cell
differentiation when administered alone (data not shown).
Since GUO effects might be due to adenosine receptor
activation (Dal-Cim et al., 2012), we next assessed adenosine
receptors involvement by adding selective antagonists for A1
(DPCPX, 100 nM), or A2A receptors (ZM241385, 50 nM) to
cell cultures treated with GUO 100 µM for 48 h. Neither
DPCPX nor ZM241385 altered the ability of GUO to enhance
SH-SY5Y cell differentiation (Figure 3A), as well as neither by
themselves, affected the behavior of untreated cells (data not
shown).
Finally, we investigated some possible signaling pathways
involved in GUO-induced neuron-like cell differentiation. As
known, pathways such as that of PI3K, PKC, and cGMP play a
key role in many physiological functions including cell
differentiation (Heikkilä et al., 1993; Kimura et al., 1994; Bau
et al., 2005). Thus, we analyzed their participation in the GUO
effect, adding selective inhibitors of PKC (GF1094002, 1 µM), or
PI3K (LY294002, 25 µM), or sGC (ODQ, 10 µM) to the culture
medium treated with GUO 100 µM for 48 h. The PKC and sGC
inhibitors reduced GUO-induced differentiation by about 24 and
31% respectively, while the PI3K inhibitor did not affect it
(Figure 3B). Since either HO-1 or NOS can stimulate sGC
(Cary and Marletta, 2001), to further investigate the upstream
pathways involved in cGMP formation, cells were exposed, to
L-NAME (5 µM) or ZnPP (1 µM), the selective inhibitors of NOS
or HO activity, respectively. As shown in Figure 3C, the HO
inhibitor, but not the NOS inhibitor, significantly reduced the
GUO effect on neuron-like cell differentiation.
Exogenous Guanosine Added to SH-SY5Y
Cell Cultures was Metabolized to Guanine
It is known that GUO is intracellularly metabolized to GUA by
PNP enzyme. We recently found that PNP is also present in
human plasma (Giuliani et al., 2016) and that rat C6 glioma cells,
astrocytes, and microglial cells (Giuliani et al., 2017; Peña-
Altamira et al., 2018), can release PNP in the extracellular
milieu. Thus, to better analyze the impact of GUO on cell
differentiation, we examined the metabolic fate of GUO in our
cultures. By HPLC analysis, we found that GUO (100 µM) added
to the cell cultures was no longer present extracellularly after 48 h,
while the concentration of GUA, its direct metabolite, was 112 ±
18 µM. To avoid interference with serum, in which PNP is
present, a serum-free medium was used and cell cultures were
treated with 100 µM GUO for 24 h, a time period in which cell
viability was not modified by serum absence (Supplementary
Figure S1). In this condition, exogenous GUO levels decreased
over time, while increasing concentrations of GUA concurrently
appeared in the medium (Figure 4A).
We also evaluated PNP activity inside and outside cells. At the
two time periods considered (6 and 24 h), in both untreated and
GUO-treated cells, the intracellular PNP activity was constant
over time (Figure 4B) and was always higher than the
extracellular one (Figure 4C). On the contrary, outside the
cells, the enzyme activity was higher after 24 h either in
FIGURE 2 | Guanosine increases the expression of specific mature neuronal markers in SH-SY5Y neuroblastoma cells. SH-SY5Y cells were cultured for 48 h
without treatment (a) or in the presence of 100 µMGUO (b) or 10 µM RA (c). βIII-Tubulin and MAP2 filaments are highlighted in green while nuclei are stained in blue with
DAPI. For NeuN expression, on the left side of the image nuclei are stained in green with NeuN while on the right side of the image nuclei are stained in blue with DAPI.
Images are representative of one of three independent experiments.
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untreated and treated cells (Figure 4C), indicating that these cells
were able to release PNP that accumulated in the extracellular
milieu. Interestingly, GUO treatment was not effective in
modulating PNP release since PNP activity was not modified
vs. untreated cells (Figure 4C). When added to the reaction
mixture, the PNP inhibitor, forodesine 1 μM, prevented the
formation of GUA, thus confirming the specificity of the
enzymatic assay.
DISCUSSION
The treatment of patients with high-risk NB remains a challenge
since even after surgical resection, chemo- and radiotherapy,
relapse is common and can depend on the presence of poorly
differentiated cells (Whittle et al., 2017). For this reason,
differentiating agents are used in the attempt to eradicate
minimal residual disease, thus improving the clinical
outcome. Even if some differentiating agents have been
identified, only RA is used but, unfortunately, resistance to
this treatment is frequent (Whittle et al., 2017), highlighting the
need to identify new potential agents. Among purine
compounds, GUO may behave as a potential differentiating
agent; thus, this study was designed to evaluate its neuritogenic
effect on NB cells. Here, we have chosen the SH-SY5Y cells since
it is a human-derived NB cell line and this should avoid species
differences in the interpretation of data. Furthermore, since
serum present in the culture medium contains many substances
that can affect cell differentiation (Brunner et al., 2010) and its
composition can vary from one lot to the next, to reduce serum
interferences and experimental variations, we used a culture
medium containing the lowest concentration of serum that did
not affect cell survival, that is, 1% FBS, as the most suitable
experimental condition.
Upon these experimental conditions, we showed that GUO
was effective in inducing SH-SY5Y cell differentiation in a time-
and concentration-dependent manner, as revealed by the
increased number of neurite-bearing cells. Furthermore, the
changes in cell morphology and neurite length were also
associated with an increased presence of mature neuronal
markers indicating their differentiation into neuronal-like cells.
Although several studies have shown that GUO promotes cell
differentiation of different cell types (Di Liberto et al., 2016), here
we presented further new data for SH-SY5Y cells. Noteworthy,
GUO was effective in inducing differentiation of PC12 cells and
B16F10 melanoma cells (Gysbers and Rathbone, 1996; Bau et al.,
2005; Naliwaiko et al., 2008) that, like SH-SY5Y NB cells, share a
common neural crest origin. Furthermore, in melanoma cells,
FIGURE 3 | Mechanisms involved in guanosine-induced SH-SY5Y neuroblastoma cell differentiation. (A) Nucleoside transporter blockers (10 µM NBTI plus
100 µM propentofylline–PPF-plus 10 µM dypiridamole -DIP-) were simultaneously added to the medium containing 1% serum 1 h before GUO (100 µM) treatment and
until the end of the experiment (48 h), while the antagonist of A1 and A2A adenosine receptor, DPCPX (100 nM) and ZM241385 (50 nM), respectively, were added 30 min
before and until the end of the 48 h GUO (100 µM) treatment period. (B) The selective inhibitors of PI3K (25 µM LY294002), PKC (1 µM GF109203X), and sGC
(10 µMOQD) or (C) the selective inhibitors of NOS (5 μML-NAME), HO (1 µM ZnPP) and sGC (10 µMOQD) were added to cultures before the addition of GUO (100 µM)
and during all the GUO treatment. In all cases, after 48 h, the total number of neurite-bearing cells was determined. Each value represents the mean ± SEM of at least five
independent experiments in duplicate and is expressed as a percentage of neurite-bearing cells vs. untreated cells. Statistical analysis was performed using one-way
ANOVAwith the Dunnett’s or Turkey’s post-hocmultiple comparisons test; *p < 0.05, **p < 0.02, ****p < 0.001 compared with untreated cells; #p < 0.05, # #p < 0.02, # #
#p < 0.01 compared with GUO treated cells.
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GUO strongly decreased cell motility, thereby contributing to
reduce tumor malignancy. GUO has also been evaluated as a
potential therapeutic agent in several types of neoplasms such as
lung cancer and hepatoma (Yang et al., 2005; Su et al., 2010) and it
has been shown to increase the antitumor effect of
chemotherapeutic agents such as 5′-deoxyfluorouridine,
acriflavine, and temozolomide (Iigo et al., 1987; Kim et al.,
1997; Oliveira et al., 2017). Furthermore, while
chemotherapeutic agents can upregulate several pro-metastatic
and pro-survival factors and are associated with high toxicity to
non-tumor cells (Ratajczak et al., 2013), there is no evidence of
serious adverse effects after systemic administration of GUO
(Schmidt et al., 2010; Jackson and Mi, 2014). Overall, these
considerations suggest GUO as an interesting potential
antitumor agent to be used, maybe, in combination with other
conventional agents in a multimodal fashion.
After having established that GUO stimulated neuron-like cell
differentiation, we next investigated the possible mechanism of
action and the signaling pathways behind this effect. Importantly,
GUO-mediated neuritogenesis was not abolished when its uptake
was blocked by nucleoside transporter inhibitors, thus indicating
that this effect was mainly exerted by extracellular GUO. These
data agree with our previous findings (Giuliani et al., 2012a;
Giuliani et al., 2015) confirming that, besides displaying several
intracellular roles, GUO can be considered an extracellular
signaling molecule. However, while specific GUO binding sites
have been found on rat brain membranes (Traversa et al., 2002;
Traversa et al., 2003; Volpini et al., 2011; Frinchi et al., 2020), the
identity of these membrane proteins have not yet been
unequivocally identified. Interestingly, an indirect mechanism
has been proposed by which GUO exerts its effect via adenosine
receptor-mediated signaling, in particular A1, A2A receptors, and
A1/A2A receptor heteromers (Dal-Cim et al., 2012; Lanznaster
et al., 2019). However, in our hands, neither the A1 nor the A2A
selective receptor antagonists modified the GUO-mediated
differentiation effect. These results corroborate the hypothesis
that GUO might act through putative specific sites distinct from
adenosine A1 and A2A receptors.
Many diseases, such as cancers, require treatment with a
combination of drugs to obtain superior effects or to prevent
the emergence of resistance. Therefore, the identification of
molecular mechanisms involved in GUO-induced
differentiation is of fundamental relevance since combination
of drugs that target different cellular pathways may work
synergistically to cell killing. Starting from the evidence that
GUO activated some signaling pathways including PI3K, PKC,
and sGC (Bau et al., 2005; Nailiwaiko et al., 2008; Dal-Cim et al.,
2012; Giuliani et al., 2015), which have long been recognized to be
also involved in neurite outgrowth (Heikkila et al., 1993; Kimura
et al., 1994; Bau et al., 2005), here we tested the activity of selective
FIGURE 4 |Metabolic fate of extracellular guanosine and purine nucleoside phosphorylase (PNP) activity in SH-SY5Y cell cultures. (A)GUO (100 µM) was added to
the culture medium containing 0% serum. At the indicated times, an aliquot of the medium was taken and analyzed by HPLC as described in materials and methods. (B)
PNP activity was measured within SH-SY5Y neuroblastoma cells or (C) in the culture medium. For this purpose, SH-SY5Y cells were incubated in a serum-free medium
supplemented or not with 100 µMGUO. After 6 and 24 h, an aliquot of the medium was taken and the enzyme present was concentrated using Amicon Ultra filters
while cells were scraped in lysis buffer and cytosolic extracts were prepared. PNP activity was assayed using 100 μMGUO as substrate plus 50 mM Pi as co-substrate
for 15 min at 37°C. The concentration of the newly formed product, GUA, was measured by HPLC analysis. PNP activity was expressed as milli-International Units (mIU)
per mg protein or ml of culture medium. Values are the mean ± SEM of at least five independent experiments, each run in duplicate. Statistical analysis was performed
using a two-way ANOVA followed by Turkey’s multiple comparison test, *p < 0.05 compared with untreated cells at 6 h and #p < 0.05 compared with GUO treated cells
at 6 h.
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inhibitors of those signals on GUO-mediated neurite outgrowth.
While the PI3K pathway was not involved, PKC and sGC
signaling pathways are required for the GUO effect since their
inhibition strongly attenuated differentiation. However, since
neither PKC nor sGC inhibitor completely abolished GUO-
effect, we believe that GUO-induced differentiation requires
the activation of further signal transductions, such as a cyclic
adenosine monophosphate pathway, as reported in other cells
(Gysbers and Rathbone, 1996). This aspect needs to be still
investigated in SH-SY5Y cells.
Noteworthy, since GUO signal is also linked to the activation
of enzymes such as HO or NOS, leading to increased production
of CO or NO, respectively, which in turn stimulate sGC to
generate cGMP (Cary and Marletta, 2001; Cary et al., 2006;
Ryter et al., 2006), we investigated whether HO or NOS were
involved in the GUO-induced effect. Our data demonstrated that
HO or sGC inhibitors decreased the GUO effect while the NOS
inhibitor was ineffective. These data corroborate those observed
in PC12 cells (Bau et al., 2005) and strengthen the importance of
the HO/sGC pathway in GUO-induced differentiation.
Finally, we could not overlook that cell purine homeostasis is
ensured by a complex network of enzymes, localized both intra-
and extracellularly, and by membrane transporters, and that
enzymes controlling purine metabolism play a key role in
regulating the biological effects of extracellular purines
(Volonté and D’Ambrosi, 2009). Thus, since GUO was added
to the culture medium for a long time, we studied its metabolic
fate in the extracellular medium. Indeed, after 48 h exogenously
administered, GUOwas no longer present in the culture medium,
whereas we detected only GUA. Exogenous GUO could be taken
up into the cells, transformed into GUA, and then released
outside the cells. Indeed, we found a strong PNP activity
inside SH-SY5Y cells. Nonetheless, there is also the possibility
that GUO could be metabolized extracellularly. Unlike
ectonucleotidases (that convert nucleotides into nucleosides),
the presence of extracellular enzymes metabolizing purine
nucleosides and nucleobases is still a matter of debate.
However, since no GUO kinase exists in mammals (Ipata,
2001), the first step in the metabolism of exogenous GUO
should be its transformation into GUA by extracellular PNP.
Noteworthy, the PNP presence in the culture medium was not
due to cell death since cell viability was not modified as evaluated
by MTT test, and PNP activity increased along time without
modification upon GUO treatment. Overall, these data
corroborate those already found in rat glioma C6 cells and in
rat astrocytes and microglial cells (Giuliani et al., 2017; Peña-
Altamira et al., 2018) and further support the existence of a
constitutive release of PNP from cells that, in these experiments,
was unaffected by GUO treatment. Data on GUO metabolic fate
raise some questions. Indeed, recent studies highlighted biological
effects also for GUA (Giuliani et al., 2012b; Zuccarini et al., 2018),
although some signaling pathways involved in the GUO pro-
differentiating effect are peculiar of GUO rather than GUA (e.g.,
HO and PKC) (Zuccarini et al., 2018). In this perspective, it is
noteworthy that Garozzo et al. (2010) found that GUA, more
than GUO, can exert antiproliferation effects in human glioma
cell lines; however, this effect was mainly due to an intracellular
effect, while in the present study, the GUO effect was mainly
extracellularly mediated since nucleoside transporter
inhibitors did not abolish it. The evaluation of a potential
GUA role in NB cell differentiation is currently being tested,
and some preliminary pilot experiments conducted using
forodesine, to inhibit the degradation of exogenous added
GUO, did not seem to modify GUO-induced differentiation,
but further experiments will be addressed to unravel the
interplay between GUO, PNP, and GUA to identify new
therapeutic targets.
In conclusion, findings from this study demonstrate that GUO
is effective in inducing NB cell differentiation, activating a process
in which some molecular mechanisms have in part been
identified (such as PKC, HO, and sGC cascades). Indeed, these
results open a new perspective for NB treatment, thus further
investigation on the role of GUA and the functioning of the
complex guanine-based purine signaling in NB cell
differentiation might yield relevant implications for NB
therapeutic purposes.
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